Whilst acknowledging the small sample size (n = 32) and the limitations of this study design, our findings demonstrated the intracranial efficacy of ARX788 for active BrMs in HER2-positive breast cancer patients previously treated with trastuzumab, taxanes, and tyrosine kinase inhibitor (TKI)-containing treatments. The gene discussed is ERBB2; the disease is breast carcinoma.